NO20061645L - Mekanismebasert, malrettet pankreasbetacellesynliggjoring og terapi - Google Patents

Mekanismebasert, malrettet pankreasbetacellesynliggjoring og terapi

Info

Publication number
NO20061645L
NO20061645L NO20061645A NO20061645A NO20061645L NO 20061645 L NO20061645 L NO 20061645L NO 20061645 A NO20061645 A NO 20061645A NO 20061645 A NO20061645 A NO 20061645A NO 20061645 L NO20061645 L NO 20061645L
Authority
NO
Norway
Prior art keywords
therapy
beta cell
pancreatic beta
cell visualization
targeted pancreatic
Prior art date
Application number
NO20061645A
Other languages
English (en)
Other versions
NO336658B1 (no
Inventor
Dong-Fang Yu
David J Yang
Chang-Sok Oh
Jr Jerry L Bryant
Saady Kohanim
Ali Azhdarinia
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of NO20061645L publication Critical patent/NO20061645L/no
Publication of NO336658B1 publication Critical patent/NO336658B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Preparater til synliggjøring av betaceUer som omfatter chelator-antidiabetiske middelkonjugater og eventuelt chelaterte metaller.
NO20061645A 2003-09-17 2006-04-11 Preparat for synliggjøring av pankreas og fremgangsmåte for synliggjøring av en pattedyrpankreas ved administrering av preparatet NO336658B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50368303P 2003-09-17 2003-09-17
PCT/US2004/030374 WO2005027981A1 (en) 2003-09-17 2004-09-16 Mechanism-based targeted pancreatic beta cell imaging and therapy

Publications (2)

Publication Number Publication Date
NO20061645L true NO20061645L (no) 2006-04-11
NO336658B1 NO336658B1 (no) 2015-10-12

Family

ID=34375381

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061645A NO336658B1 (no) 2003-09-17 2006-04-11 Preparat for synliggjøring av pankreas og fremgangsmåte for synliggjøring av en pattedyrpankreas ved administrering av preparatet

Country Status (16)

Country Link
US (2) US7611693B2 (no)
EP (2) EP1675625B1 (no)
JP (3) JP5395327B2 (no)
KR (2) KR20110119813A (no)
CN (1) CN1867363B (no)
AU (1) AU2004273911B2 (no)
BR (1) BRPI0414512B8 (no)
CA (1) CA2539384C (no)
DK (1) DK1675625T3 (no)
ES (1) ES2403378T3 (no)
HK (1) HK1094312A1 (no)
IL (1) IL174374A (no)
NO (1) NO336658B1 (no)
PL (1) PL1675625T3 (no)
PT (1) PT1675625E (no)
WO (1) WO2005027981A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611693B2 (en) * 2003-09-17 2009-11-03 Board Of Regents, The Univerisity Of Texas System Mechanism-based targeted pancreatic beta cell imaging and therapy
WO2006104401A1 (en) * 2005-03-26 2006-10-05 Protemix Corporation Limited Copper antagonist compositions
AU2006266229B2 (en) * 2005-06-29 2013-02-21 The Trustees Of Columbia University In The City Of New York Use of DTBZ for imaging endocrine pancreas and beta cell mass in type 1 diabetes
WO2008038302A2 (en) * 2006-09-26 2008-04-03 Jegannathan Srinivas Therapeutic formulation comprising a sulfonylurea, metformin and a nitric oxide scavenger.
WO2008038304A2 (en) * 2006-09-26 2008-04-03 Jegannathan Srinivas Therapeutical formulation comprising an alpha-glucosidase inhibitor and a nitric oxide scavenger.
CA2719623A1 (en) 2008-03-24 2009-10-01 The Board Of Regents Of The University Of Texas System Image-guided therapy of myocardial disease: composition, manufacturing and applications
EP2460542A4 (en) * 2009-07-31 2015-02-18 Riken ENDOKRINER PANCREAS CELL INDICATOR AND ITS USE

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2951135A1 (de) 1979-12-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
JPS57102820A (en) 1980-12-19 1982-06-26 Nippon Mejifuijitsukusu Kk Agent for radiodiagnosis
JPS5944329A (ja) 1982-09-07 1984-03-12 Nippon Mejifuijitsukusu Kk 新規な放射性診断剤
JPS59193833A (ja) 1983-04-19 1984-11-02 Nippon Mejifuijitsukusu Kk 新規な二官能配位子化合物含有放射性診断剤
US4732864A (en) 1983-10-06 1988-03-22 E. I. Du Pont De Nemours And Company Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules
JPS6354321A (ja) 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
JPH01186899A (ja) * 1988-01-18 1989-07-26 Nippon Mejifuijitsukusu Kk 膜透過性を有するＴｃ−９９ｍ単核錯体
MY106120A (en) * 1988-12-05 1995-03-31 Novartis Ag Peptide derivatives.
US5094837A (en) 1990-01-22 1992-03-10 Wayne State University Method for use of magnetic resonance imaging to image pancreas using secretin
US4994258A (en) 1990-03-05 1991-02-19 Merck & Co., Inc. Gamma emitting, CCK-A antagonists for pancreatic imaging
FR2661187B1 (fr) 1990-04-20 1994-08-05 Inst Nat Sante Rech Med Proteine associee a la pancreatite aiguue. moyens pour le diagnostic de la pancreatite aiguue.
JPH05186372A (ja) 1991-07-18 1993-07-27 Green Cross Corp:The 脂肪乳剤及びｍｒｉ診断用造影剤
US5463116A (en) 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
JP3465247B2 (ja) 1992-12-28 2003-11-10 アベンティス ファーマ株式会社 動脈硬化症の予防および治療剤
US5656600A (en) * 1993-03-25 1997-08-12 Corvas International, Inc. α-ketoamide derivatives as inhibitors of thrombosis
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
DE4336159A1 (de) 1993-10-22 1995-04-27 Kurt Heinz Prof Dr Bauer Hochwirksame, den Wirkstoff schnell oder kontrolliert freisetzende Zubereitungsformen von Sulfonylharnstoffen und Verfahren zu deren Herstellung
US5763200A (en) * 1995-05-12 1998-06-09 Biomeasure, Incorporated Inhibition of amylin release
WO1998033531A1 (en) * 1997-02-03 1998-08-06 Mallinckrodt Medical, Inc. Method for the detection and localization of malignant human tumours
WO2000023603A2 (en) 1998-10-21 2000-04-27 Arch Development Corporation Methods of treatment of type 2 diabetes
US6358491B1 (en) * 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
JP4822039B2 (ja) * 1999-12-28 2011-11-24 味の素株式会社 経口投与用糖尿病薬製剤
SK14922002A3 (sk) * 2000-03-17 2003-04-01 Ajinomoto Co., Inc. Farmaceutický prostriedok na prevenciu, zlepšenie a/alebo liečenie diabetickej komplikácie a použitie postprandiálnej látky na zníženie hladiny krvného cukru
AU2001285145A1 (en) 2000-08-21 2002-03-04 Millennium Pharmaceuticals, Inc. Human abc transporter family member and uses thereof
AU2002338572A1 (en) 2001-04-13 2002-11-11 Millennium Pharmaceuticals, Inc. 66784, a novel human potassium channel and uses therefor
US7611693B2 (en) * 2003-09-17 2009-11-03 Board Of Regents, The Univerisity Of Texas System Mechanism-based targeted pancreatic beta cell imaging and therapy

Also Published As

Publication number Publication date
KR20110119813A (ko) 2011-11-02
CN1867363B (zh) 2010-05-12
EP2474328A2 (en) 2012-07-11
US20100278731A1 (en) 2010-11-04
KR20060104984A (ko) 2006-10-09
NO336658B1 (no) 2015-10-12
US20050100506A1 (en) 2005-05-12
AU2004273911A1 (en) 2005-03-31
JP2015078223A (ja) 2015-04-23
PT1675625E (pt) 2013-05-23
AU2004273911B2 (en) 2010-04-15
PL1675625T3 (pl) 2013-08-30
EP1675625A4 (en) 2009-07-15
EP1675625A1 (en) 2006-07-05
KR101152729B1 (ko) 2012-06-15
US7611693B2 (en) 2009-11-03
WO2005027981A1 (en) 2005-03-31
DK1675625T3 (da) 2013-05-13
BRPI0414512B8 (pt) 2021-05-25
JP2007505915A (ja) 2007-03-15
CN1867363A (zh) 2006-11-22
JP5395327B2 (ja) 2014-01-22
EP1675625B1 (en) 2013-02-20
HK1094312A1 (en) 2007-03-30
BRPI0414512A (pt) 2006-11-07
CA2539384A1 (en) 2005-03-31
ES2403378T3 (es) 2013-05-17
JP2011052016A (ja) 2011-03-17
EP2474328A3 (en) 2012-07-18
CA2539384C (en) 2012-08-28
IL174374A0 (en) 2006-08-01
IL174374A (en) 2011-12-29
BRPI0414512B1 (pt) 2020-11-17

Similar Documents

Publication Publication Date Title
NO20061645L (no) Mekanismebasert, malrettet pankreasbetacellesynliggjoring og terapi
NO20005224L (no) BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse
NO20062649L (no) Biarylsulfonamider og metoder for anvendelse av disse
DK1487763T3 (da) Anvendelse af mikrofremstillede indretninger til radiosyntese
TR200100054T2 (tr) Paroksetin metansülfonat
NO20014935D0 (no) Middel for forbedring av ketose
NO20090305L (no) Cyklosporin formuleringer
DK1404377T3 (da) Forbedrede chelatorkonjugater
DK1426054T3 (da) Medicinsk anvendelse af histon-deacetylase-inhibitor og fremgangsmåde til evaluering af antitumor virkning deraf
DK1282663T3 (da) Gel af et poly-a-1,4-glucan og stivelse
DK1511734T3 (da) Forbindelser, præparater og fremgangsmåder
NO20032788D0 (no) Modafinil-forbindelse og cyklodekstrinblandinger
DK1560826T3 (da) Pyridopyrimidinonderivater, fremgangsmåde til fremstiling heraf og farmaceutiske sammensætninger indeholdende disse
DE602004007824D1 (de) Kationisch härtbare zusammensetzung
DK1476438T3 (da) Oxa- og thiadiazoler og deres anvendelse som metalloproteinaseinhibitorer
DK1553942T3 (da) Farmaceutisk præparat, der kombinerer tenatoprazol og et antiinflammatorisk middel
NO20061316L (no) Imidazopyndinderivater som induserbare NO-syntaseinhibitorer
DK1379508T3 (da) N-(aryl)-2arylethensulfonamider og terapeutiske anvendelser deraf
BR0308660A (pt) C-17 espirolactonização e 6,7 oxidação de esteróides
NO20053071L (no) Kalsilytiske forbindelser.
ATE404602T1 (de) Wässrige polyurethanzubereitungen
WO2007032005A3 (en) Novel amine-borane compounds and uses thereof
AU7548901A (en) Liposomal encapsulation of chelated actinium-225 and uses thereof
EE200400085A (et) 2-amino-6-(2,4,5-asendatud fenüül)püridiinid kasutamiseks lämmastikoksiidi süntaasi inhibiitoritena
AU2003226459A1 (en) Improver premix for chapatis comprising ascorbic acid, sodium stearoyl lactylate and guar gum